<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479216</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1211-1791</org_study_id>
    <nct_id>NCT03479216</nct_id>
  </id_info>
  <brief_title>Comparison of Intra-articular Dexmedetomidine and Magnesium in Postoperative Pain</brief_title>
  <official_title>Comparison of Intra-articular Dexmedetomidine and Magnesium in Postoperative Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derince Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Derince Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arthroscopic meniscus surgeries are the most frequent orthopedic procedures. The objective of
      the study is to compare the effects of intraarticular local anesthetic and adjuvant
      (dexmedetomidine vs magnesium) combinations in postoperative pain and analgesic requirement.
      The investigators' hypothesis is adjuvants added to the local anesthetics decreases the total
      local anesthetic dose, provides more effective pain relief according to local anesthetic
      only, and decreases the postoperative systemic non-steroidal analgesic and opioid doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arthroscopic meniscus surgeries are the most frequent orthopedic procedures. However,
      irritation of free nerve endings in the synovial tissue and anterior fat pads and stretching
      and resection in the joint capsule lead to pain at various levels. Proper pain management
      enhances recovery, provides early mobilization and shortens length of hospital stay.

      &quot;Opioid-free&quot; analgesia methods are frequently emphasized in published postoperative pain
      management guidelines and multimodal treatment approaches such as local anesthetic
      infiltration is recommended. In the treatment of knee pain, intra-articular drug injections
      are the most commonly used method because of minimal systemic side effects.

      The drugs most commonly administered intraarticularly included local anesthetics
      (bupivacaine, levobupivacaine, lidocaine), opioids (morphine, fentanyl), magnesium sulfate,
      steroids, and α2 agonists (clonidine, dexmedetomidine).

      Dexmedetomidine is a selective, specific, lipophilic and potent α2 adrenergic receptor
      agonist with sedative, anxiolytic, analgesic, antihypertensive and sympatholytic effects. It
      provides analgesic activity through both the central and peripheral nervous system. The
      analgesic effects of intra-articular administration of dexmedetomidine in arthroscopic
      surgeries have been demonstrated. Most side effects of this drug included hypotension and
      bradycardia. However, these side effects have never been encountered with intra-articular
      injection of the drug.

      Magnesium is also an adjuvant drug which has a key role in nociceptive transmission, and acts
      as a NMDA (N-Methyl-D-Aspartate) antagonist in spinal neurons.

      While opioid free anesthesia and analgesia methods gain importance nowadays, there has been
      increased interest in non-opioid analgesic drugs and multimodal analgesia applications. In
      order to increase the effects of local anesthetics and prolong their analgesic times, the
      addition of various adjuvants to local anesthetics is frequently used.

      In the randomized controlled trials, intraarticular local anesthetic drugs combined with
      adjuvant drugs for postoperative analgesia were found to be superior to local anesthetic
      drugs alone. It is also known that local anesthetics have negative effects on chondrocytes.
      One of the goals of the investigators' in this study is to reduce the amount of local
      anesthetic used by adding adjuvant to local anesthetics.

      In this study, the investigators plan to compare the efficacy of 2 adjuvants (magnesium
      sulfate and dexmedetomidine) combined with local anesthetics to be given intraarticularly for
      postoperative pain management after elective arthroscopic surgery.

      Intraarticular high-volume drug injections may cause pain due to tension in the joint
      capsule. Additionally, the investigators aim to decrease the total drug volume with adjuvant
      drugs used in combination with local anesthetic, and thus to prevent joint capsule tension
      pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Actual">August 1, 2018</completion_date>
  <primary_completion_date type="Actual">July 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>24 hours</time_frame>
    <description>postoperative pain scores (rest and movement) (ward) Pain scores were assessed with a 10-cm Visual Analogue Scale (VAS) (with 0 = no pain and 10 = the worst imaginable pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Opioid/NSAID Consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>nonsteroid antiinflammatory drugs (NSAID) or opioid drugs that are applied to patients will be noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Analgesic Time</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to first analgesic demand at the orthopedics ward (from intraarticular injection to first analgesic requirement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery Time</measure>
    <time_frame>24 hours</time_frame>
    <description>time from skin incision to closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the End of Spinal Anesthesia</measure>
    <time_frame>24 hours</time_frame>
    <description>time from the start of spinal anesthesia (total block = Bromage 3) to the end of spinal anesthesia (Bromage 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobilization</measure>
    <time_frame>24 hours</time_frame>
    <description>First mobilization time after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complications Due to Intraarticular Injection</measure>
    <time_frame>24 hours</time_frame>
    <description>post-injection complications due to intraarticular injection will be noted.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Intra-articular Injection</condition>
  <condition>Dexmedetomidine</condition>
  <condition>Magnesium Sulfate</condition>
  <arm_group>
    <arm_group_label>Precedex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium Sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Precedex</intervention_name>
    <description>10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.</description>
    <arm_group_label>Precedex</arm_group_label>
    <other_name>bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.</description>
    <arm_group_label>Magnesium Sulfate</arm_group_label>
    <other_name>bupivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18, &lt;65

          -  scheduled for elective knee arthroscopy under spinal anesthesia

          -  ASA I and ASA II

        Exclusion Criteria:

          -  age &lt;18 and &gt;65

          -  patients who received general anesthesia

          -  diabetes

          -  refusal of the patient

          -  known allergy to the specified drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tolga K Saracoglu, Ass Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Derince Training and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Derince Training and Research Hospital</name>
      <address>
        <city>Kocaeli</city>
        <state>Derince</state>
        <zip>41900</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Sun R, Zhao W, Hao Q, Tian H, Tian J, Li L, Jia W, Yang K. Intra-articular clonidine for post-operative analgesia following arthroscopic knee surgery: a systematic review and meta-analysis. Knee Surg Sports Traumatol Arthrosc. 2014 Sep;22(9):2076-84. doi: 10.1007/s00167-013-2615-8. Epub 2013 Jul 24. Review.</citation>
    <PMID>23881255</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang Y, Zeng C, Wei J, Li H, Yang T, Deng ZH, Li YS, Yang TB, Lei GH. Single-dose intra-articular bupivacaine plus morphine versus bupivacaine alone after arthroscopic knee surgery: a meta-analysis of randomized controlled trials. Knee Surg Sports Traumatol Arthrosc. 2017 Mar;25(3):966-979. doi: 10.1007/s00167-015-3748-8. Epub 2015 Aug 12.</citation>
    <PMID>26264382</PMID>
  </results_reference>
  <results_reference>
    <citation>Gerlach AT, Dasta JF. Dexmedetomidine: an updated review. Ann Pharmacother. 2007 Feb;41(2):245-52. Epub 2007 Feb 13. Review. Erratum in: Ann Pharmacother. 2007 Mar;41(3):530-1.</citation>
    <PMID>17299013</PMID>
  </results_reference>
  <results_reference>
    <citation>Alipour M, Tabari M, Faz RF, Makhmalbaf H, Salehi M, Moosavitekye SM. Effect of dexmedetomidine on postoperative pain in knee arthroscopic surgery; a randomized controlled clinical trial. Arch Bone Jt Surg. 2014 Mar;2(1):52-6. Epub 2014 Mar 15.</citation>
    <PMID>25207314</PMID>
  </results_reference>
  <results_reference>
    <citation>Li C, Qu J. Efficacy of dexmedetomidine for pain management in knee arthroscopy: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Oct;96(43):e7938. doi: 10.1097/MD.0000000000007938. Review.</citation>
    <PMID>29068980</PMID>
  </results_reference>
  <results_reference>
    <citation>Heydari SM, Hashemi SJ, Pourali S. The Comparison of Preventive Analgesic Effects of Ketamine, Paracetamol and Magnesium Sulfate on Postoperative Pain Control in Patients Undergoing Lower Limb Surgery: A Randomized Clinical Trial. Adv Biomed Res. 2017 Oct 25;6:134. doi: 10.4103/2277-9175.217217. eCollection 2017.</citation>
    <PMID>29279832</PMID>
  </results_reference>
  <results_reference>
    <citation>Kızılcık N, Özler T, Menda F, Uluçay Ç, Köner Ö, Altıntaş F. The effects of intra-articular levobupivacain versus levobupivacain plus magnesium sulfate on postoperative analgesia in patients undergoing arthroscopic meniscectomy: A prospective randomized controlled study. Acta Orthop Traumatol Turc. 2017 Mar;51(2):104-109. doi: 10.1016/j.aott.2017.02.014. Epub 2017 Mar 15.</citation>
    <PMID>28314555</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <results_first_submitted>August 9, 2018</results_first_submitted>
  <results_first_submitted_qc>November 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2018</results_first_posted>
  <last_update_submitted>November 8, 2018</last_update_submitted>
  <last_update_submitted_qc>November 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Derince Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Hande G. Aytuluk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Analgesia</keyword>
  <keyword>Anesthesia</keyword>
  <keyword>Arthroscopy</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Injections, Intra-Articular</keyword>
  <keyword>Magnesium</keyword>
  <keyword>Pain, Postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>not decided yet</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT03479216/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>History of cardiac, hepatic or renal disorders, diabetes mellitus, chronic pain treatment, contraindication to/refusal of spinal anesthesia, a known allergy to the study drugs, or who refused to participate in the study were excluded.
(10 patients excluded: 5 declined regional anesthesia, 4 had diabetes mellitus,1 failure of regional anesthesia)</recruitment_details>
      <pre_assignment_details>52 patients aged between 18 and 65 years with ASA I or II who were scheduled for elective arthroscopic meniscectomy under spinal anesthesia were included in this prospective, randomized, double-blind study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Precedex</title>
          <description>5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
Precedex: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.</description>
        </group>
        <group group_id="P2">
          <title>Magnesium Sulfate</title>
          <description>5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
Magnesium Sulfate: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Precedex</title>
          <description>5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
Precedex: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.</description>
        </group>
        <group group_id="B2">
          <title>Magnesium Sulfate</title>
          <description>5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
Magnesium Sulfate: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.62" lower_limit="18" upper_limit="65"/>
                    <measurement group_id="B2" value="42.73" lower_limit="23" upper_limit="59"/>
                    <measurement group_id="B3" value="42.18" lower_limit="18" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="26"/>
                    <count group_id="B3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Pain</title>
        <description>postoperative pain scores (rest and movement) (ward) Pain scores were assessed with a 10-cm Visual Analogue Scale (VAS) (with 0 = no pain and 10 = the worst imaginable pain)</description>
        <time_frame>24 hours</time_frame>
        <population>visual analogue scale (VAS) scores at rest at 2nd hour (VAS2 R), 4th hour (VAS4 R), 6th hour (VAS6 R), 8th hour (VAS8 R), 12th hour (VAS12 R), 18th hour (VAS18 R) VAS scores at movement at 2nd hour (VAS2 M), 4th hour (VAS4 M), 6th hour (VAS6 M), 8th hour (VAS8 M), 12th hour (VAS12 M), 18th hour (VAS18 M)</population>
        <group_list>
          <group group_id="O1">
            <title>Precedex</title>
            <description>5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
Precedex: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
          <group group_id="O2">
            <title>Magnesium Sulfate</title>
            <description>5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
Magnesium Sulfate: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain</title>
          <description>postoperative pain scores (rest and movement) (ward) Pain scores were assessed with a 10-cm Visual Analogue Scale (VAS) (with 0 = no pain and 10 = the worst imaginable pain)</description>
          <population>visual analogue scale (VAS) scores at rest at 2nd hour (VAS2 R), 4th hour (VAS4 R), 6th hour (VAS6 R), 8th hour (VAS8 R), 12th hour (VAS12 R), 18th hour (VAS18 R) VAS scores at movement at 2nd hour (VAS2 M), 4th hour (VAS4 M), 6th hour (VAS6 M), 8th hour (VAS8 M), 12th hour (VAS12 M), 18th hour (VAS18 M)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS 2 R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS2 M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0.23" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS4 R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.12" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS4 M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="1.19" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS6 R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="1.31" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS6 M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="3.31" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS8 R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="1.77" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS8 M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="4.08" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS12 R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="1.15" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS12 M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="3.19" lower_limit="2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS18 R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.27" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS18 M</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="1.69" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Opioid/NSAID Consumption</title>
        <description>nonsteroid antiinflammatory drugs (NSAID) or opioid drugs that are applied to patients will be noted.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Precedex</title>
            <description>5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
Precedex: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
          <group group_id="O2">
            <title>Magnesium Sulfate</title>
            <description>5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
Magnesium Sulfate: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Opioid/NSAID Consumption</title>
          <description>nonsteroid antiinflammatory drugs (NSAID) or opioid drugs that are applied to patients will be noted.</description>
          <units>vials</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NSAID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>opioid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Analgesic Time</title>
        <description>Time to first analgesic demand at the orthopedics ward (from intraarticular injection to first analgesic requirement)</description>
        <time_frame>24 hours</time_frame>
        <population>Time to first analgesic demand at the orthopedics ward (from intra-articular injection to first analgesic requirement) was calculated in minutes among patients who required analgesics</population>
        <group_list>
          <group group_id="O1">
            <title>Precedex</title>
            <description>5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
Precedex: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
          <group group_id="O2">
            <title>Magnesium Sulfate</title>
            <description>5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
Magnesium Sulfate: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Analgesic Time</title>
          <description>Time to first analgesic demand at the orthopedics ward (from intraarticular injection to first analgesic requirement)</description>
          <population>Time to first analgesic demand at the orthopedics ward (from intra-articular injection to first analgesic requirement) was calculated in minutes among patients who required analgesics</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477.33" lower_limit="240" upper_limit="840"/>
                    <measurement group_id="O2" value="498.46" lower_limit="330" upper_limit="750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgery Time</title>
        <description>time from skin incision to closure</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Precedex</title>
            <description>5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
Precedex: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
          <group group_id="O2">
            <title>Magnesium Sulfate</title>
            <description>5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
Magnesium Sulfate: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Surgery Time</title>
          <description>time from skin incision to closure</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.23" lower_limit="15" upper_limit="35"/>
                    <measurement group_id="O2" value="25.58" lower_limit="15" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the End of Spinal Anesthesia</title>
        <description>time from the start of spinal anesthesia (total block = Bromage 3) to the end of spinal anesthesia (Bromage 0)</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Precedex</title>
            <description>5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
Precedex: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
          <group group_id="O2">
            <title>Magnesium Sulfate</title>
            <description>5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
Magnesium Sulfate: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the End of Spinal Anesthesia</title>
          <description>time from the start of spinal anesthesia (total block = Bromage 3) to the end of spinal anesthesia (Bromage 0)</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.1" lower_limit="60" upper_limit="320"/>
                    <measurement group_id="O2" value="147.5" lower_limit="70" upper_limit="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mobilization</title>
        <description>First mobilization time after surgery</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Precedex</title>
            <description>5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
Precedex: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
          <group group_id="O2">
            <title>Magnesium Sulfate</title>
            <description>5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
Magnesium Sulfate: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mobilization</title>
          <description>First mobilization time after surgery</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.27" lower_limit="75" upper_limit="300"/>
                    <measurement group_id="O2" value="139.42" lower_limit="75" upper_limit="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complications Due to Intraarticular Injection</title>
        <description>post-injection complications due to intraarticular injection will be noted.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Precedex</title>
            <description>5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
Precedex: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
          <group group_id="O2">
            <title>Magnesium Sulfate</title>
            <description>5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
Magnesium Sulfate: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complications Due to Intraarticular Injection</title>
          <description>post-injection complications due to intraarticular injection will be noted.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>an average of 1 month (from hospitalization to re-admissions due to complications (if any))</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Precedex</title>
          <description>5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
Precedex: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.</description>
        </group>
        <group group_id="E2">
          <title>Magnesium Sulfate</title>
          <description>5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
Magnesium Sulfate: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hande Aytuluk</name_or_title>
      <organization>Derince Training and Research Hospital</organization>
      <phone>00905336515650</phone>
      <email>handegrbz@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

